Genmab — Maj 2020

[Helge_LarsenPI-redaktør]

Tak for links E L.

[E_L]

lol. let's put the DuoHexa up also:

[E_L]

DUOHEXABODY-CD37 SHOWS POTENT ANTI-TUMOR ACTIVITY IN PRE-CLINICAL B-CELL LYMPHOMA MODELS IN VITRO AND IN VIVO https://library.ehaweb.org/eha/2020/eha25th/293801/marije.b.overdijk.duohexabody-cd37.shows.potent.anti-tumor.activity.in.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Dduohexabody

[GeorgeBest]

tak Pensionisten - 15:14

[E_L]

hang on, one more by Mrs Mateos even:

[E_L]

A PHASE 1 STUDY OF TECLISTAMAB, A HUMANIZED B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) https://library.ehaweb.org/eha/2020/eha25th/295026/marie-victoria.mateos.a.phase.1.study.of.teclistamab.a.humanized.b-cell.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Dteclistamab

[Bulder]

Janssens bcma car-t har 100% ORR, 86% sCR men eet dødsfald pga CRS. http://johnsonandjohnson.gcs-web.com/static-files/8d6cdaa2-dcfb-4e49-9151-fcd8162f2df5

[Bulder]

Heavily pretreated pts

[E_L]

yes, it is getting a bit more press than the bcma/cd3. but i am glad JNJ feels comfortable showing it out now, had been so quiet about it

[E_L]

"CD38-knockout NK cells, which have been designed in attempt to prevent fratricide and enhance the activity of daratumumab" https://twitter.com/MM_Hub/status/1260948019689795589

[Solsen]

At the moment its no competitor to dara. I think we now can say no thread to dara the next 5 years either from Takeda or JNJ.

[E_L]

you mean the JNJ car-t?

[Solsen]

yes

[Solsen]

I still think its for the last choise - due to sideeffects (possible grade 5) and price.

[E_L]

yea, think so too. Jan said that from the beginning, didn't he. The market clearly overshot in car-t optimism when it first came out, where in this chat most have been relatively negative

[Solsen]

With Car-T you manipulate with the immune system in a way that you dont have 100% control. Some pts just suddenly die.

[Solsen]

Perhaps not many but to many to first, second and perhaps third line.

[Solsen]

And thats where the big money are.

[Bulder]

Nevertheless it is very positive,that in the late lines, when all other options are used, there still is a possibility to have a sCR.

[Solsen]

You are so right !